Navigation Links
Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone

Interim results in a randomized phase II/III clinical trial anticipated later this year

SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced the publication of preclinical studies, which demonstrate that treatment with pixantrone (BBR 2778) resulted in minimal or no significant cardiotoxicity, while doxorubicin and mitoxantrone induced significant cardiac damage. The studies compared the cardiac side effects of equiactive doses of pixantrone to doxorubicin and mitoxantrone in mice pre-treated with a cardiotoxic dose of doxorubicin as well as in mice without prior treatment. The article was published in the June 2007 journal Investigational New Drugs.

"In preclinical hematological tumor models pixantrone showed higher effectiveness and minimal or lack of cardiotoxicity as compared to mitoxantrone or doxorubicin. The findings reported in this article strongly support the clinical potential of pixantrone as a replacement for currently marketed anthracyclines. We hope our randomized phase II/III RAPID (PIX203) study in first-line aggressive NHL will confirm these preclinical results in patients and possibly diminish the most serious side effect associated with current standard treatments -- irreversible heart damage," said Gabriella Pezzoni, Ph.D., Scientific Director at Cell Therapeutics Europe S.r.l. (Milan).

In spite of their dose-dependent cardiotoxic effects, anthracyclines are still considered the standard of care because of their efficacy in several tumor types, including breast cancer, leukemia, and non-Hodgkin's lymphoma (NHL). Because of the irreversible nature of the cardiac damage that accompanies the use of currently marketed anthracyclines, patients who are treated with these agents are subject to a maximum cumulative life-time dose, which may result in premature discontinuation of therapy and limit the physician's ability to use this active class of a
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:4/16/2015)... 2015  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) will ... on Wednesday, May 6, 2015, following the close of the ... conference call and live webcast on the same day at ... discuss the financial results.  To access the ... the "Investors" link.  Please log onto the webcast prior to ...
(Date:4/16/2015)... Kenneth C. Frazier , chairman and chief executive officer ... the Board of the Pharmaceutical Research and Manufacturers of America ... John J. Castellani announced that he will be retiring ... to PhRMA Board Frazier formerly held the position ... and CEO of Pfizer, Inc. Also elected were George ...
(Date:4/16/2015)... YORK , April 16, 2015 An ... additional way to generate trimers from the major HIV ... could benefit future clinical development of HIV vaccine candidates ... the critical target on the surface of HIV for ... an important platform for AIDS vaccine discovery, says ...
Breaking Medicine Technology:Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5New Method Holds Promise for HIV Vaccine Development 2
... Corporation (Nasdaq: GNBT, www.generex.com ), the leader in ... of the mouth, today announced that it has been ... Canadian Intellectual Property Office granted Canadian Patent No. 2,401,942, ... Application". This new patent increases the number ...
... International Corporation (Nasdaq: PRXL ) announced today it ... Conference in New York.  James Winschel, Senior Vice President and ... at 11:45 a.m. ET on Tuesday, October 5, 2010. ... through the "Investors" section of PAREXEL,s website at ...
Cached Medicine Technology:Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System 2Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System 3PAREXEL International to Present at William Blair Emerging Growth Stock Conference 2
(Date:4/19/2015)... The American Institute for Cancer Research (AICR) ... to host its second annual, nationwide Shred Cancer event. ... in order to raise funds for cancer research and ... event is being held at 20+ PROSHRED locations throughout ... time will vary at select locations. , Individuals are ...
(Date:4/19/2015)... WI (PRWEB) April 19, 2015 HealthPostures, ... announces that it will exhibit it’s pioneering ergonomics ... Expo and the Iowa-Illinois Safety Council Professional Development Conference ... and the TaskMate EZ are used in volume by ... facilities. , Built to clamp to a desk, ...
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog ... cheaper during Spring. , Spring can be a ... should make sure they compare the newest policies before ... learn more about Spring car insurance offers by reading ... quotes are becoming more and more popular. Many insurance ...
(Date:4/18/2015)... has released a new blog post explaining how to ... Clients can review important auto insurance quotes online, by ... advantages for clients who need affordable financial security for ... coverage for their vehicles can purchase a policy at ... agencies offer important discounts and drivers can learn more ...
(Date:4/18/2015)... the past few weeks, TheBeautyPlace.com has been undergoing maintenance ... run maintenance on our shipping facilities to update software ... Director. "It disrupted our regular shipping schedule but we ... track after having completed the maintenance." , Now, TheBeautyPlace.com ... has not allowed some calls to come in through ...
Breaking Medicine News(10 mins):Health News:2015 Annual Nationwide "Shred Cancer" Shredding Event 2Health News:HealthPostures' TaskMate Products to be Exhibited at the Wisconsin and Iowa-Illinois Safety Conferences 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:TheBeautyPlace.com Temporary Number Available 2
... poor, has banned the life-threatening practice of female circumcision, the ... in female genital mutilation (FGM) would be punished with a ... follows a campaign against the practice by the National Union ... women are circumcised. ,'Female circumcision is a ...
... of a Canadian university have voted overwhelmingly to remove ... company has implemented// unethical practices in India and Colombia. ... University of Guelph voted last week to remove Coca-Cola ... to India Resource Center, an international campaigning organization that ...
... the developing world? Look at Galway, the third largest city in ... Scores of people have taken ill and tens of thousands are ... ,Water supply in Galway has been hit by an outbreak of ... to have been hit by a serious stomach bug as a ...
... company, Crucell N V’s Rabies monoclonal antibody (mAb) product ... four months after launching// a similar study in the ... monoclonal antibody product for the post-exposure prophylaxis of rabies, ... phase I study is closely linked to the initial ...
... of low-sugar potato, as there is an increasing demand across ... trend is particularly evident in Gujarat in western India, where ... to the new variety. ,The low-sugar potato is ... processing firms snap up the produce without any delay, farmers ...
... major, Intercell and its partner Hyderabad-based Biological E. ... to start// a pediatric phase II clinical trial ... ,The randomized and controlled study aims ... Intercell’s JE vaccine compared to a locally produced ...
Cached Medicine News:Health News:Eritrea Bans Female Circumcision 2Health News:Water Crisis Wreaks Havoc on Irish City 2Health News:Crucell's Rabies MAb Enters Phase I Trial in India 2
Micro-hematocrit tubes available in multiple sizes and additives for a wide range of capillary blood collection....
... The Vivid 3 system is designed ... of cardiovascular performance, and offer an even ... pediatrics and the OR. From color flow ... connectivity, the new Vivid 3 offers a ...
... 4 system is an easy-to-use, high-performance ultrasound ... your clinical practice. In effect, GE has ... a value-based combination of proven technology and ... paid heed to features praised by Vivid ...
... remote monitoring from Medtronic is changing the ... care. Using their Medtronic CareLink Monitor and ... send device information from their home or ... site, clinicians have the ability to review ...
Medicine Products: